Anne-Margreeth Krijger-Dijkema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Margreeth Krijger-Dijkema has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hanno Pijl
Leiden University Medical Center
2 shared publications - Ben van Ommen
TNO, Zeist, The Netherlands
1 shared publication - Guy E. H. M. Rutten
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
1 shared publication - Iris M. de Hoogh
Department of Human Performance, Unit Defence, Safety and Security, Netherlands Organization for Applied Scientific Research (TNO) , Soesterberg 3769DE
1 shared publication - Johanneke E. Oosterman
Research Group Microbiology & Systems Biology, TNO, Netherlands Organization for Applied Scientific Research, 3700 AJ Zeist, The Netherlands
1 shared publication - Nathalie Wilmsen
Huisarts en medisch adviseur, MSc, voedingswetenschapper, Amsterdam, Nederland
1 shared publication
Latest Publications
- 12 November 2021
- Published by Springer Nature in Nederlands Tijdschrift voor Diabetologie
- Vol. 19 (4) , 54-59
Insulinetherapie bij diabetes mellitus type 2: hoe veilig is dat?
- 12 November 2021
- Published by Springer Nature in Nederlands Tijdschrift voor Diabetologie
- Vol. 19 (4) , 54-59
Insulinetherapie bij diabetes mellitus type 2: hoe veilig is dat?
- Open Access
The Effect of a Lifestyle Intervention on Type 2 Diabetes Pathophysiology and Remission: The Stevenshof Pilot Study
Although lifestyle interventions can lead to diabetes remission, it is unclear to what extent type 2 diabetes (T2D) remission alters or improves the underlying pathophysiology of the disease. Here, we assess the effects of a lifestyle intervention on T2D reversal or remission and the effects on the underlying pathology. In a Dutch primary care setting, 15 adults with an average T2D duration of 13.4 years who were (pharmacologically) treated for T2D received a diabetes subtyping (“diabetyping”) lifestyle intervention (DLI) for six months, aiming for T2D remission. T2D subtype was determined based on an OGTT. Insulin and sulphonylurea (SU) derivative treatment could be terminated for all participants. Body weight, waist/hip ratio, triglyceride levels, HbA1c, fasting, and 2h glucose were significantly improved after three and six months of intervention. Remission and reversal were achieved in two and three participants, respectively. Indices of insulin resistance and beta cell capacity improved, but never reached healthy values, resulting in unchanged T2D subtypes. Our study implies that achieving diabetes remission in individuals with a longer T2D duration is possible, but underlying pathology is only minimally affected, possibly due to an impaired beta cell function. Thus, even when T2D remission is achieved, patients need to continue adhering to lifestyle therapy.
Open AccessThe Effect of a Lifestyle Intervention on Type 2 Diabetes Pathophysiology and Remission: The Stevenshof Pilot Study
Although lifestyle interventions can lead to diabetes remission, it is unclear to what extent type 2 diabetes (T2D) remission alters or improves the underlying pathophysiology of the disease. Here, we assess the effects of a lifestyle intervention on T2D reversal or remission and the effects on the underlying pathology. In a Dutch primary care setting, 15 adults with an average T2D duration of 13.4 years who were (pharmacologically) treated for T2D received a diabetes subtyping (“diabetyping”) lifestyle intervention (DLI) for six months, aiming for T2D remission. T2D subtype was determined based on an OGTT. Insulin and sulphonylurea (SU) derivative treatment could be terminated for all participants. Body weight, waist/hip ratio, triglyceride levels, HbA1c, fasting, and 2h glucose were significantly improved after three and six months of intervention. Remission and reversal were achieved in two and three participants, respectively. Indices of insulin resistance and beta cell capacity improved, but never reached healthy values, resulting in unchanged T2D subtypes. Our study implies that achieving diabetes remission in individuals with a longer T2D duration is possible, but underlying pathology is only minimally affected, possibly due to an impaired beta cell function. Thus, even when T2D remission is achieved, patients need to continue adhering to lifestyle therapy.